Literature DB >> 7028641

Increased multiclonal antibody-forming cell activity in the peripheral blood of patients with SLE.

T M Becker, E F Lizzio, B Merchant, J P Reeves, A D Steinberg.   

Abstract

21 patients with criteria for systemic lupus erythematosus (SLE) and 12 normal controls were studied for their spontaneous circulating IgM and IgG plaque-forming cells (PFCs) reactive against sheep erythrocytes (SRBC) and against a panel of five haptens. Quantitatively defined active and mildly active SLE patients had significantly elevated IgM- and IgG-producing PFCs in their peripheral blood reactive with the panel of five chemically defined haptens. Those patients having inactive SLE also showed increased circulating IgM PFCs. Significant elevations in circulating hapten-reactive PFCs were found to correlate progressively with disease activity in the inactive, mildly active, and active SLE patient groups. Circulating IgM- and IgG-secreting PFC reactive against SRBC were both significantly elevated only in those patients with active SLE. The data support the concept that SLE patients have a generalized increase in B cell activity against a broad repertoire of determinants, even those ostensibly unrelated to natural tissue antigens.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028641     DOI: 10.1159/000232833

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  2 in total

1.  Use of recombinant RNP peptides 70K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients.

Authors:  D J de Rooij; W J Habets; L B van de Putte; M H Hoet; A L Verbeek; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

2.  Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease.

Authors:  P M Houtman; C G Kallenberg; P C Limburg; M G Huitema; M H van Rijswijk; T H The
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.